AUPH
Aurinia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$16.08
−0.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 311.5M | 283.1M | 235.1M | 175.5M | 134.0M |
| Cost of Revenue | 30.0M | 32.7M | 28.2M | 14.1M | 5.7M |
| Gross Profit | 281.5M | 250.4M | 206.9M | 161.4M | 128.4M |
| Operating Expenses | |||||
| R&D Expense | 39.9M | 32.5M | 20.8M | 49.6M | 45.0M |
| SG&A Expense | 101.0M | 101.8M | 172.0M | 195.0M | 196.4M |
| General & Admin Expense | 99.3M | 98.6M | 157.9M | 195.0M | 196.4M |
| Selling & Marketing Expense | 1.7M | 3.2M | 14.1M | — | — |
| Other Expenses | (10.1M) | 11.2M | 18.8M | 8.4M | (1.5M) |
| Total Operating Expenses | 130.7M | 145.5M | 211.6M | 253.1M | 239.8M |
| Cost and Expenses | 160.8M | 178.1M | 239.8M | 267.2M | 245.5M |
| Operating Income (EBIT) | 150.7M | 104.9M | (4.7M) | (91.7M) | (111.5M) |
| Non-Operating | |||||
| Interest Income | 13.7M | 13.6M | 17.0M | 17.0M | 5.1M |
| Interest Expense | 8.5M | 4.3M | 4.8M | 2.8M | — |
| Net Interest Income | 5.2M | 9.2M | 12.1M | 14.2M | 5.1M |
| Other Non-Op Income/Expense | 9.6M | 9.2M | 12.1M | 14.2M | 5.1M |
| Non-Operating Income (excl Interest) | (18.1M) | (13.6M) | (17.0M) | (17.0M) | (5.1M) |
| EBT (Pre-Tax Income) | 160.4M | 114.2M | 7.4M | (77.5M) | (106.4M) |
| Income Tax Expense | (153.8M) | (173.0M) | 1.7M | 551.0K | 1.8M |
| Bottom Line | |||||
| Net Income | 314.1M | 287.2M | 5.8M | (78.0M) | (108.2M) |
| Earnings from Cont. Ops | 314.1M | 287.2M | 5.8M | (78.0M) | (108.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 314.1M | 287.2M | 5.8M | (78.0M) | (108.2M) |
| Per Share | |||||
| Basic EPS | $2.36 | $2.14 | $0.04 | ($0.54) | ($0.76) |
| Diluted EPS | $2.29 | $2.07 | $0.04 | ($0.54) | ($0.76) |
| Revenue Per Share | $2.39 | $2.11 | $1.64 | $1.23 | $0.94 |
| Shares | |||||
| Basic Shares Outstanding | 130.1M | 134.4M | 143.1M | 143.2M | 141.9M |
| Diluted Shares Outstanding | 133.5M | 138.7M | 146.2M | 143.2M | 141.9M |
| Profitability Metrics | |||||
| EBITDA | 188.2M | 127.8M | 31.7M | (63.0M) | (103.6M) |
| D&A | 19.4M | 9.3M | 19.4M | 11.6M | 2.7M |
| EBIT | 168.8M | 118.5M | 12.3M | (74.7M) | (106.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026